Compare Adaptive Biotechnologies Corp (ADPT) vs Under Armour Inc Class A (UAA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Under Armour Inc Class A — how do they compare? Adaptive Biotechnologies Corp trades at $25.16 (market cap $4.04B), while Under Armour Inc Class A trades at $5.23 (market cap $2.26B). The key difference: Adaptive Biotechnologies Corp is the larger of the two by market cap, and Adaptive Biotechnologies Corp is trading nearer its 52-week high, Under Armour Inc Class A nearer its low. Which is the better fit depends on your goals.
| ADPT | UAA | |
|---|---|---|
Market Cap | $4.04B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $25.45 | $8.14 |
52-Week Low | $12.30 | $4.17 |
Enterprise Value | $4.10B | $3.24B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Under Armour (UAA) trades at $5.86, down 4.09% today, reflecting ongoing challenges. The stock shows a bearish technical trend with support near $5.00. Fundamentally, the company reported a net loss of -$201.27M in 2025 with a negative net margin of -9.99%, though recent Q2 2026 earnings beat expectations. Revenue declined to $5.16B in 2025, and cash flow turned negative at -$361.87M. Analyst sentiment is mixed with a consensus price target of $6.67 but a majority hold rating.
The outlook remains cautious due to weak North American demand and margin pressures. Investment opportunities exist if the company executes its full-price strategy successfully, but risks include persistent revenue declines and high debt levels. The stock's proximity to its low price target of $5.00 underscores downside vulnerability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Under Armour Inc Class A
Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →
